Cytosine Arabinoside as a Modulator in Ewing Sarcoma
Author Information
Author(s): Kimberly Stegmaier, Jenny S. Wong, Kenneth N. Ross, Kwan T. Chow, David Peck, Renee D. Wright, Stephen L. Lessnick, Andrew L. Kung, Todd R. Golub
Primary Institution: Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School
Hypothesis
Screening small-molecule libraries highly enriched for FDA-approved drugs will provide a more rapid path to clinical application for Ewing sarcoma treatment.
Conclusion
The study identifies cytosine arabinoside (ARA-C) as a potent modulator of the EWS/FLI oncoprotein in Ewing sarcoma, warranting clinical trials.
Supporting Evidence
- ARA-C reduced EWS/FLI protein abundance and diminished cell viability.
- ARA-C abrogated tumor growth in a xenograft model.
- Clinical trials testing ARA-C are warranted due to its safety profile.
Takeaway
Researchers found that a drug called ARA-C can help treat a type of cancer called Ewing sarcoma by targeting a specific protein that helps the cancer grow.
Methodology
A gene expression signature for the EWS/FLI off state was determined using microarray profiling, followed by screening a small-molecule library enriched for FDA-approved drugs.
Limitations
The study primarily focuses on in vitro and xenograft models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website